{
    "sponsor_name": "",
    "study_acronym": "",
    "tested_imp": "apixaban",
    "comparative_drug": "",
    "study_type": "",
    "interventional_study_phase": "",
    "study_design": "",
    "aim_of_study": "",
    "target_disease": "",
    "type_of_randomization": "",
    "randomization_stratification": [],
    "apixaban_dosing": "",
    "dalteparin_dosing": "",
    "apixaban_supply_form": "",
    "dalteparin_supply_form": "",
    "scheduled_visits": [],
    "primary_efficacy_outcome": "",
    "secondary_efficacy_outcomes": [],
    "primary_safety_outcome": "",
    "secondary_safety_outcomes": [],
    "maximum_sample_size_per_arm": 0,
    "recommended_inclusion_criteria": [],
    "recommended_exclusion_criteria": [
        "acute hepatitis",
        "chronic active hepatitis",
        "liver cirrhosis",
        "ALT level \u22653 times the upper limit of normal (ULN)",
        "bilirubin level \u22652 times the ULN",
        "hepatic disease associated with coagulopathy and a clinically relevant bleeding risk",
        "severe hepatic impairment"
    ]
}